Enanta Q3 Loss Narrows, RSV Drug Advances to Late-Stage Trials
ENTA has more than doubled off its 52-week low of $6.45.
Summary
Enanta reported a fiscal Q3 net loss of $19.5M ($0.67/share) on $14.4M in royalty revenue, with cash of $211.5M expected to fund operations into fiscal 2029. The loss narrowed from $0.85/share a year ago, but revenue declined from $18.3M due to lower AbbVie HCV sales. More importantly, the company disclosed significant pipeline progress: dosing has begun in the LOTUS Phase 2b pediatric RSV trial, and a registrational Phase 2b/3 trial (RESOLVE) in high-risk adults is set to start in Q4 2026, with initial data next year. In immunology, topline Phase 1 data for EDP-978 is due in Q4 2026, and an IND filing for STAT6 inhibitor EPS-3903 is planned this year. These updates follow the recent $75M ATM offering and the June patent loss on Paxlovid, adding clinical catalysts that could reshape the outlook. The RSV program's advancement into registrational trials is a key value driver, with no approved antiviral therapies currently available.
At the time of this announcement, ENTA was trading at $13.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $401.6M. The 52-week trading range was $6.45 to $17.15. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: BusinessWire.